Efficacy of Infliximab in Disease Control of Refractory Orbital Myositis

References

• Pakdaman MN, Sepahdari AR, Elkhamary SM. Orbital inflammatory disease: pictorial review and differential diagnosis. World J Radiol. 2014;6(4):106–115. doi:10.4329/wjr.v6.i4.106.
   PubMedGoogle Scholar
• Schoser BG. Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease - five new cases and review. Clin Ophthalmol. 2007;1:37–42.
   PubMedGoogle Scholar
• Harris GJ. Idiopathic orbital inflammation: a pathogenetic construct and treatment strategy: the 2005 ASOPRS Foundation Lecture. Ophthalmic Plast Reconstr Surg. 2006;22(2):79–86. doi:10.1097/01.iop.0000203734.52333.93.
   PubMed Web of Science ®Google Scholar
• Slavin ML, Glaser JS. Idiopathic orbital myositis: report of six cases. Arch Ophthalmol. 1982;100(8):1261–1265. doi:10.1001/archopht.1982.01030040239005.
   PubMedGoogle Scholar
• Trokel SL, Hilal SK. Recognition and differential diagnosis of enlarged extraocular muscles in computed tomography. Am J Ophthalmol. 1979;87(4):503–512. doi:10.1016/0002-9394(79)90239-3.
   PubMed Web of Science ®Google Scholar
• Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003;121(4):491–499. doi:10.1001/archopht.121.4.491.
   PubMedGoogle Scholar
• Scott IU, Siatkowski RM. Idiopathic orbital myositis. Curr Opin Rheumatol. 1997;9:504–512.
   PubMedGoogle Scholar
• Trokel SL, Jakobiec FA. Correlation of CT scanning and pathologic features of ophthalmic Graves’ disease. Ophthalmology. 1981;88:553–564.
   PubMed Web of Science ®Google Scholar
• Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology. 1997;104(3):402–408. doi:10.1016/S0161-6420(97)30301-7.
   PubMed Web of Science ®Google Scholar
• Yan J, Wu P. Idiopathic orbital myositis. J Craniofac Surg. 2014;25(3):884–887. doi:10.1097/SCS.0000000000000510.
   PubMed Web of Science ®Google Scholar
• Gordon LK. Orbital inflammatory disease: a diagnostic and therapeutic challenge. Eye (Lond). 2006;20(10):1196–1206. doi:10.1038/sj.eye.6702383.
   PubMed Web of Science ®Google Scholar
• Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol. 2001;85(10):1220–1224. doi:10.1136/bjo.85.10.1220.
   PubMed Web of Science ®Google Scholar
• Garrity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol. 2004;138(6):925–930. doi:10.1016/j.ajo.2004.06.077.
   PubMed Web of Science ®Google Scholar
• Zurlo A, Sancesario G, Bernardi G, Loasses A. Orbital pseudotumor: case report and literature review. Tumori. 1999;85(1):68–70. doi:10.1177/030089169908500115.
   PubMed Web of Science ®Google Scholar
• Smitt MC, Donaldson SS. Radiation therapy for benign disease of the orbit. Semin Radiat Oncol. 1999;9(2):179–189. doi:10.1016/S1053-4296(99)80008-3.
   PubMed Web of Science ®Google Scholar
• Costa RM, Dumitrascu OM, Gordon LK. Orbital myositis: diagnosis and management. Curr Allergy Asthma Rep. 2009;9(4):316–323. doi:10.1007/s11882-009-0045-y.
   PubMed Web of Science ®Google Scholar
• Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149–160. doi:10.1002/path.2287.
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, Van Den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol. 2004;52(1):61–63. doi:10.1159/000079547.
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Martinez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarres M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford). 2004;43(9):1196–1197. doi:10.1093/rheumatology/keh285.
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350(21):2167–2179. doi:10.1056/NEJMra032906.
   PubMed Web of Science ®Google Scholar
• Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2002;14(3):204–211. doi:10.1097/00002281-200205000-00002.
   PubMed Web of Science ®Google Scholar
• Sikora JP, Chlebna-Sokol D, Dabrowska I, Lipczynski D, Chrul S. Proinflammatory cytokine inhibitors, TNF-alpha and oxidative burst of polymorphonuclear leukocytes in the pathogenesis of sepsis in newborns. Arch Immunol Ther Exp (Warsz). 2001;49:155–161.
   PubMed Web of Science ®Google Scholar
• Sahlin S, Lignell B, Williams M, Dastmalchi M, Orrego A. Treatment of idiopathic sclerosing inflammation of the orbit (myositis) with infliximab. Acta Ophthalmol. 2009;87(8):906–908. doi:10.1111/j.1755-3768.2008.01320.x.
   PubMed Web of Science ®Google Scholar
• Donaldson SS, McDougall IR, Egbert PR, Enzmann DR, Kriss JP. Treatment of orbital pseudotumor (idiopathic orbital inflammation) by radiation therapy. Int J Radiat Oncol Biol Phys. 1980;6(1):79–86. doi:10.1016/0360-3016(80)90207-2.
   PubMed Web of Science ®Google Scholar
• Culver EL, Salmon JF, Frith P, Travis SP. Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn’s disease: case report and systematic literature review. J Crohn’s Colitis. 2008;2(4):337–342. doi:10.1016/j.crohns.2008.06.002.
   Google Scholar
• Taddio A, Cattalini M, Simonini G, Cimaz R. Recent advances in the use of anti-TNFalpha therapy for the treatment of juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2016;12(6):641–649. doi:10.1586/1744666X.2016.1146132.
   PubMed Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, Van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89(5):533–536. doi:10.1136/bjo.2003.037192.
   PubMed Web of Science ®Google Scholar
• Adams AB, Kazim M, Lehman TJ. Treatment of orbital myositis with Adalimumab (Humira). J Rheumatol. 2005;32:1374–1375.
   PubMed Web of Science ®Google Scholar
• Hernandez-Garfella ML, Gracia-Garcia A, Cervera-Taulet E, Garcia-Villanueva C, Montero-Hernandez J. Adalimumab for recurrent orbital myositis in Crohn’s disease: report of a case with a 3-year follow-up. J Crohn’s Colitis. 2011;5(3):265–266. doi:10.1016/j.crohns.2011.02.010.
   Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149:550–561.e510.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;121(12):2387–2392. doi:10.1016/j.ophtha.2014.07.007.
   PubMed Web of Science ®Google Scholar
• Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol. 2001;13(3):164–169. doi:10.1097/00002281-200105000-00003.
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10):1885–1888. doi:10.1212/WNL.57.10.1885.
   PubMed Web of Science ®Google Scholar
• Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96(3):722–729. doi:10.1111/j.1572-0241.2001.03612.x.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, Baert F, D’Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56:1226–1231.
   PubMed Web of Science ®Google Scholar